Literature DB >> 27045977

Failure pattern and salvage treatment after radical treatment of head and neck cancer.

Anja Pagh1, Cai Grau2, Jens Overgaard1.   

Abstract

Purpose The aim of the study was to test the hypothesis that head and neck cancer (HNC) patients benefit from specialized follow-up (FU), as this strategy ensures timely detection of relapses for successful salvage treatment. This was done by evaluation of the pattern of failure, the temporal distribution of recurrences, and the outcome of salvage treatment in a contemporary cohort of HNC patients. Methods The study evaluated a cohort of 2062 consecutive patients treated with curative intent at Aarhus University Hospital from 1 January 2000 to 31 December 2013. The database of DAHANCA contained recordings of recurrent disease in 567 patients with primary tumors of the larynx, pharynx, oral cavity, nasal cavity, paranasal sinuses and salivary glands. A review of medical records was performed in order to update and supplement the database. Results Failures of the 567 patients were primarily in T-site (65%) followed by N-site (36%) and M-site (22%). The vast majority of the first recurrences occurred within the first years after primary treatment; 62%, 82%, and 91% within the first, second and third year, respectively. Totally, 51% were amenable for salvage treatment, and 44% benefited from salvage in terms of a complete response. Permanent tumor control was observed in 128 patients (23%) after one or two salvage attempts. The highest salvage rate was recorded in patients with primary glottic carcinoma (41%) and the lowest among hypopharyngeal cancers (2%). Asymptomatic recurrence was recorded in 12% of all recurrences and this was found to be a positive prognostic factor for disease-specific survival, as they had significantly better outcome after salvage. Conclusion Our data support the usefulness of specialized FU in terms of early detection of recurrent disease. In particular patients with silent recurrences benefited from early detection, as they had a significantly lower risk ratio of death from primary HNC.

Entities:  

Mesh:

Year:  2016        PMID: 27045977     DOI: 10.3109/0284186X.2015.1117136

Source DB:  PubMed          Journal:  Acta Oncol        ISSN: 0284-186X            Impact factor:   4.089


  10 in total

1.  Prognostic value of the radiomics-based model in progression-free survival of hypopharyngeal cancer treated with chemoradiation.

Authors:  Xiaokai Mo; Xiangjun Wu; Di Dong; Baoliang Guo; Changhong Liang; Xiaoning Luo; Bin Zhang; Lu Zhang; Yuhao Dong; Zhouyang Lian; Jing Liu; Shufang Pei; Wenhui Huang; Fusheng Ouyang; Jie Tian; Shuixing Zhang
Journal:  Eur Radiol       Date:  2019-10-30       Impact factor: 5.315

2.  To do or not to do: salvage management for hypopharyngeal cancer after chemoradiation therapy.

Authors:  Pei-Hsin Chu; Ngan-Ming Tsang; Li-Ang Lee; Chun-Ta Liao; Tuan-Jen Fang
Journal:  Eur Arch Otorhinolaryngol       Date:  2018-06-20       Impact factor: 2.503

3.  Co-registration of radiotherapy planning and recurrence scans with different imaging modalities in head and neck cancer.

Authors:  Morten Horsholt Kristensen; Christian Rønn Hansen; Ruta Zukauskaite; Jørgen Johansen; Eva Samsøe; Christian Maare; Anne Ivalu Sander Holm; Jesper Grau Eriksen
Journal:  Phys Imaging Radiat Oncol       Date:  2022-06-30

4.  Persistent Head and Neck Cancer Following First-Line Treatment.

Authors:  Teresa Bernadette Steinbichler; Madeleine Lichtenecker; Maria Anegg; Daniel Dejaco; Barbara Kofler; Volker Hans Schartinger; Maria-Therese Kasseroler; Britta Forthuber; Andrea Posch; Herbert Riechelmann
Journal:  Cancers (Basel)       Date:  2018-11-03       Impact factor: 6.639

5.  Surgical rescue for persistent head and neck cancer after first-line treatment.

Authors:  Teresa Bernadette Steinbichler; L Golm; D Dejaco; D Riedl; B Kofler; C Url; D Wolfram; H Riechelmann
Journal:  Eur Arch Otorhinolaryngol       Date:  2020-01-25       Impact factor: 2.503

6.  Survival Outcomes and Predictors for Patients who Failed Chemoradiotherapy/Radiotherapy and Underwent Salvage Total Laryngectomy.

Authors:  Ming-Hsien Tsai; Hui-Ching Chuang; Yu-Tsai Lin; Tai-Lin Huang; Fu-Min Fang; Hui Lu; Chih-Yen Chien
Journal:  Int J Environ Res Public Health       Date:  2021-01-06       Impact factor: 3.390

7.  Clinicians' Views of Patient-initiated Follow-up in Head and Neck Cancer: a Qualitative Study to Inform the PETNECK2 Trial.

Authors:  A Lorenc; M Wells; T Fulton-Lieuw; P Nankivell; H Mehanna; M Jepson
Journal:  Clin Oncol (R Coll Radiol)       Date:  2021-12-01       Impact factor: 4.126

8.  Prediction of Incomplete Response of Primary Tumour Based on Clinical and Radiomics Features in Inoperable Head and Neck Cancers after Definitive Treatment.

Authors:  Joanna Kaźmierska; Michał R Kaźmierski; Tomasz Bajon; Tomasz Winiecki; Anna Bandurska-Luque; Adam Ryczkowski; Tomasz Piotrowski; Bartosz Bąk; Małgorzata Żmijewska-Tomczak
Journal:  J Pers Med       Date:  2022-06-30

Review 9.  Estimating survival after salvage surgery for recurrent salivary gland cancers: Systematic review.

Authors:  Giuditta Mannelli; Lara V Comini; Andrea Sacchetto; Roberto Santoro; Giuseppe Spinelli; Pierluigi Bonomo; Isacco Desideri; Paolo Bossi; Ester Orlandi; Giammarco Alderotti; Alessandro Franchi; Annarita Palomba; Albino Eccher; Daniele Marchioni; Riccardo Nocini; Cesare Piazza; Gabriele Molteni
Journal:  Head Neck       Date:  2022-04-20       Impact factor: 3.821

10.  Overlapping volumes in re-irradiation for head and neck cancer - an important factor for patient selection.

Authors:  Anna Embring; Eva Onjukka; Claes Mercke; Ingmar Lax; Anders Berglund; Sara Bornedal; Berit Wennberg; Signe Friesland
Journal:  Radiat Oncol       Date:  2020-06-08       Impact factor: 3.481

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.